Objectives: To assess the relative efficacy and safety of canagliflozin (CANA), a sodiumglucose co-transporter (SGLT) inhibitor, as add-on to metformin, compared to sulphonylureas (SU), pioglitazone, DPP-4s, GLP-1s and dapagliflozin. MethOds: Bayesian network meta-analysis was conducted based on a systematic literature review described separately. Outcomes of interest included HbA1c, weight and hypoglycaemia. Networks were based on treatment-and dose-specific nodes where possible. Non-informative priors were used; selection of fixed versus random-effect model was based on DIC. Studies causing inconsistency (identified through the comparison of direct and indirect evidence in the network) were identified with a clinical expert and excluded from the base case. Results: 25/17/7 studies reported results at 26/52/104 weeks (w) respectively. HbA1c-reduction (2) at 26w/52w was best for exenatide 2mg and liraglutide 1.8mg. CANA 300mg had a higher reduction versus DPP-4s (h= -0.11 to -0.39) and dapagliflozin 10mg (= = -0.12 to -0.38) across all time points; while CANA 100mg conferred at least as large reductions (= = 0.01 to -0.30 and 0.00 to -0.26 respectively). The analysis at 104w was conducted based on the pooling of SUs. CANA 300mg and 100mg ranked first/second before liraglutide 1.2mg/1.8mg (s= -0.11/-0.13 and -0.02/-0.04 respectively). Both CANA doses had higher weight-reductions than SU, DPP-4s and pioglitazone, and provided reductions comparable to GLP-1s and dapagliflozin. Odds ratios for hypoglycaemia versus SU ranged from 0.03 to 0.11 for DPP-4 and SGLT. cOnclusiOns: NMA of add-on therapies to metformin suggests that CANA 300mg is associated with increased HbA1creduction versus DPP-4s and dapagliflozin while CANA 100mg provides at least similar effects. Additionally, results suggest increasing relative efficacy of CANA over time versus liraglutide and CANA reached at least as large HbA1c reductions as liraglutide at 104w. Weight reduction was comparable to GLP-1s and substantially higher than all other classes. All classes showed significantly less risk of hypoglycaemia compared to SU.
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PRM194 EstiMating ChRoniC DisEasE PREVaLEnCE fRoM CLaiMs Data: REDuCing Bias By aCCounting foR DisEasED inDiViDuaLs Who Do not gEnERatE CLaiMs
Signorovitch J. 1 , De G. 2 , Drabo E. 3 , Guerin A. 4 1 Analysis Group, Inc., Boston, MA, USA, 2 Analysis Group, Inc., New York, NY, USA, 3 University of Southern California, Los Angeles, CA, USA, 4 Analysis Group, Ltee., Montreal, QC, Canada Objectives: Claims data are often used to estimate the prevalence of chronic diseases, typically by dividing the number of patients with disease-related claims (e.g., ≥ 1 or ≥ 2 claims) by the number of studied individuals. Such estimates will have a downward bias because not all diseased patients will generate diseaserelated claims within their enrollment period. This downward bias can be substantial for underserved diseases that lack effective treatments. We explored whether an empirical Bayes estimator for the number of diseased individuals who do not generate claims could improve the accuracy of claims-based prevalence estimates. MethOds: As an example, we studied the prevalence of a rare dermatological condition without any FDA-approved therapies. After accounting for enrollment time, individuals in a large nation-wide claims database were identified as having 0, 1, 2, 3, etc., disease-related claims. These counts were modeled using a mixture of Poisson distributions, with an unknown mixing distribution. Empirical Bayes approaches, which are frequently used to estimate numbers of unobserved species in ecological experiments, were used to estimate the number of diseased individuals without claims, and to provide adjusted prevalence estimates. Results: Out of over 4 million individuals with at least one year of continuous enrollment, n= 2,026 had disease-related claims, comprised of n= 1,422 with one claim, n= 317 with two claims, n= 134 with 3 claims, etc. The traditional method for estimating prevalence identified 4.9 cases per 10,000 persons. After applying the empirical Bayes approach, the estimated prevalence increased to 7.9 cases per 10,000 persons, and became closer to published prevalence estimates based on non-claims data sources. cOnclusiOns: In this example application, prevalence estimates based on claims data were increased by over 60% by using empirical Bayes approaches to account for large numbers of diseased individuals who did not generate claims. The increased prevalence estimates were more consistent with the published literature. Objectives: To analyse the applicability of copulas distribution in economic evaluation. MethOds: We have analyzed data from an observational prospective study of patients with allergic rhinitis in Spain (n= 498). Main data were direct cost (€ 2012) and Health Related Quality of Life (SF-12). We have calculated the goodness of fit for copulas (Gumbel copula, Clayton Copula, Frank Copula, Normal Copula, Plackett Copula and T copula) based on the empirical process comparing the empirical copula with a parametric estimate of the copula derived under the null hypothesis. We have used inversion of Kendall's tau method to fit copulas. A multivariate independence sample was generated to compare with copulas results. This process was replicated for a 100 times to obtain p-values by bootstrap method. Results: Marginal distribution of direct cost was a 3-parameter Gamma distribution (shape= 1.856, scale= 0.00324, location= 10.97). Marginal distribution of Health Related Quality of Life was associated to a 1-gamma (shape 2.9253 and scale 0.16104). P-value range were 0.093 to 0.144 for independent distribution, 0.004 to 0.031 for Gumbel copula, 0.246 to 0.522 for Clayton Copula, 0.545 to 0.814 for Frank Copula, 0.463 to 0.716 for Normal Copula, 0.373 to 0.628 for T Copula and 0.549 to 0.847 for Plackett Copula. Frank Copula and Plackett Copula had the best goodness of fit. Kendall's Tau for Fran Copula showed a correlation of -0.4212. cOnclusiOns: Copulas distribution allows us to adjust better the non-lineal relation between cost and effectiveness. Furthermore, this kind of approach could improve probabilistic sensitivity analyses. methods have been developed for synthesis of diverse sources of evidence: multiple outcomes (including surrogate, potentially short-term endpoints) and other external evidence. These methods were applied to an example in rheumatoid arthritis where outcomes such as the Health Assessment Questionnaire (HAQ), the Disease Activity Score (DAS-28) and the American College of Rheumatology (ACR20) are synthesized. External information about correlations between the outcomes was included in the form of informative prior distributions. Estimates of HAQ were then mapped onto EQ-5D. Also in an alternative approach, the multivariate framework was applied to model jointly the utility estimates and the clinical effectiveness outcomes. Results: The use of multivariate meta-analysis led to reduced uncertainty around the effectiveness and utility estimates. Combining the HAQ with DAS-28 gave a 19% reduction in the uncertainty around the estimate of HAQ and also 16% around the estimate of EQ-5D. cOnclusiOns: By allowing all relevant data to be incorporated in economic evaluations of new health technologies, this multivariate approach to meta-analysis can lead to reduced uncertainty and hence more efficient decision-making in health care.
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The usefulness of a multivariate approach to compare treatments in the context of pairwise meta-analysis has been widely demonstrated in the literature. However, this approach has not yet been considered for multiple treatment comparisons. We believe that extending such methodology to network meta-analysis (NMA) will increase the primary evidence base allowing us to compare more interventions across multiple outcomes measures. Borrowing strength between outcome measures using multivariate NMA can also potentially increase the precision of relative treatment effect estimates and reduce the impact of outcome reporting bias.Objectives: To extend standard NMA to incorporate multiple outcomes of interest and evaluate the use of multivariate NMA models through simulated and real datasets. MethOds: We developed a random effects multivariate NMA model to account for the correlation between multiple outcome measures. The potential benefits of this method were demonstrated in a simulated example comparing univariate and bivariate NMAs for continuous outcome measures. We further explored the application of our multivariate NMA model using a case study comparing antiobesity pharmacological interventions for waist circumference, weight change and BMI change from baseline. Results: The simulation study showed that through use of multivariate NMA the precision in mean relative treatment effects increased compared to a standard univariate NMA. This held true under multiple scenarios testing model parameters including both within-and between-outcome correlations. Similar findings were obtained from the application to the example dataset in obesity. cOnclusiOns: Our method proves particularly useful in reducing uncertainty around relative effectiveness estimates when the outcomes included for analysis are highly correlated. However, the advantages of the multivariate NMA are limited where there is little correlation between outcome measures. Further work will explore the applicability of multivariate NMA methods to different types of outcomes such as binary outcome measures. Evidera, London, UK, 2 Evidera, Barcelona, Spain, 3 Evidera, Dorval, QC, Canada, 4 Roche S.p.A., Monza, Italy Objectives: In multi-centre Time and Motion (T&M) studies, time endpoints can be highly variable due to differences in centre practices. Our aim was to assess the impact of the type of analysis employed on the results of a T&M study. MethOds: Data from 13 centres were analyzed in relation to each of the following: drug preparation, distribution, and injection, using three methods. Base case methodology included a random intercept generalized linear mixed effect model assuming gamma distribution with log link function to account for potential centre clustering effect and non-normality of the outcome measure. The two alternative methods were: standard linear regression (assuming time data are normally distributed) and gamma regression with log link function (assuming time data are positively skewed), both of which do not account for centre clustering effect. Sample means and variability as measured by 95% confidence interval (CI)) were also compared. Results: For the base case, mean time was 0.53 min (95% CI: 0.33-0.85) for "preparation", 0.30 min (95% CI: 0.22-0.40) for "distribution", and 0.81 min (95% CI: 0.59-1.11) for "injection". Mean time resulting from the standard linear regression was markedly higher for "preparation": 0.66 (95% CI: 0.59-0.73), and similar for "distribution" and "injection": 0.34 (95% CI: 0.30-0.37) and 0.84 minutes (95% CI: 0.79-0.88), respectively. Using the gamma regression yielded similar results to standard linear regression: 0.65 (95% CI: 0.59-0.71), 0.31 (95% CI: 0.29-0.34), and 0.83 minutes (95% CI: 0.79-0.88), respectively. The base case scenario detected a "centre-clustering" effect, hence producing substantially wider CIs compared to both alternative methods which ignore dependence in the data. cOnclusiOns: Although mean task times remained relatively stable across the various methods, 95% CIs were substantially wider for random intercept model. If "centre-clustering" is detected, random effects regression models must be employed to produce valid confidence intervals around point estimates.
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